Coinspeaker Gilead (GILD) Stock Falls Nearly 4% Despite Positive Remdesivir Phase 3 Trial DataDespite the fact that the latest results of remdesivir trials are inspiring, Gilead (GILD) stock is down. By the moment of writing, it has plunged 3.97% to $74.71.Gilead (GILD) Stock Falls Nearly 4% Despite Positive Remdesivir Phase 3 Trial Data